Monte Rosa Therapeutics Inc. (NASDAQ: GLUE)
$4.65
-0.2200 ( -4.52% ) 65.9K
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Market Data
Open
$4.65
Previous close
$4.87
Volume
65.9K
Market cap
$286.92M
Day range
$4.64 - $5.08
52 week range
$2.44 - $8.84
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jan 04, 2024 |
10-q | Quarterly Reports | 76 | Nov 09, 2023 |
8-k | 8K-related | 14 | Nov 09, 2023 |
8-k | 8K-related | 18 | Oct 26, 2023 |
8-k | 8K-related | 100 | Oct 17, 2023 |
3 | Insider transactions | 2 | Aug 18, 2023 |
10-q | Quarterly Reports | 73 | Aug 10, 2023 |
8-k | 8K-related | 14 | Aug 10, 2023 |
4 | Insider transactions | 1 | Jul 26, 2023 |
8-k | 8K-related | 12 | Jul 26, 2023 |